Novo Nordisk's Victoza Gains First Japanese GLP-1 Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The type 2 diabetes therapy could soon have competition though, with Lilly's Byetta pending approval and Chugai/Teijin's candidate entering Phase III.
You may also be interested in...
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
That FDA's approval of Novo Nordisk's Victoza (liraglutide) uses its full cadre of FDA Amendments Act-granted drug safety controls - a Risk Evaluation and Mitigation Strategy and mandatory post-marketing requirements - is not surprising, given the concern about a potential cancer risk. But it is a disappointment to investors
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
That FDA's approval of Novo Nordisk's Victoza (liraglutide) uses its full cadre of FDA Amendments Act-granted drug safety controls - a Risk Evaluation and Mitigation Strategy and mandatory post-marketing requirements - is not surprising, given the concern about a potential cancer risk. But it is a disappointment to investors
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
Liraglutide's US approval comes with a black box warning for a thyroid cancer risk and hefty post-marketing requirements.